Wednesday, November 27, 2024
11/27/2024
Bone loss and impairment in energy metabolism with aging prevalently lead to fractures and diabetes. As an organ, the skeleton is one of the largest consumers of energy needed for bone remodeling and maintenance of bone homeostasis. Bone remodeling is under control of osteocytes, which constitute 90-95% of bone cells, and which bioenergetic program is largely unknown. New evidence indicates that nuclear receptor PPARG, which is a global regulator of energy metabolism and pharmacological target to treat hyperglycemia, regulates osteocyte energy metabolism and their function including production of sclerostin, an inhibitor of WNT pathway activity and a key protein regulating bone remodeling. Research proposed in this application will provide an insight into the connection between osteocyte bioenergetics, its function in bone metabolism and systemic energy metabolism, and whether bone acts as the body “energostat” via osteocyte endocrine activities. The leading hypothesis is that changes in PPARG activity with aging alter osteocyte function and bioenergetics resulting in simultaneous decrease in bone formation and decrease in energy metabolism. This hypothesis will be tested in three specific aims. Aim 1 will determine how fuel choice and aging affect osteocyte function and whether these processes are PPARG dependent. With the use of aged C57BL/6 and γOTKO mice, bone organ cultures, and osteocyte-like MLO-Y4 cells with down-regulated PPARG, in combination with transcriptomics, quantitative proteomics, and coculture experiments, PPARG contribution to osteocyte aging will be defined. Aim 2 will contrast the PPARG protein interactome of osteocytes with the interactome of adipocytes, in response to either full agonist rosiglitazone or the inverse agonist SR10171, in order to define an optimal PPARG modulator for its beneficial effects on bone and metabolism. The analysis will be done on osteocyte- like MLO-Y4 cells using quantitative Tandem Mass Tag Proteomics. Aim 3 will define dynamics of PPARG interactome on PPRE sequences present in Sost promoter as a function of aging and in response to pharmacological modulation of PPARG activity. The premise of this application is to set a stage for precise pharmacologic manipulation with PPARG activities in osteocytes to simultaneously improve skeletal and metabolic dysfunction in elderly.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
